Health Condition 1: G998- Other specified disorders of nervous system in diseases classified elsewhere
Conditions
Interventions
Intervention1: Photobiomodul
ation with 940nm diode laser with carbamazepine: All patients will receive 200mg of carbamazepine twice daily along with Photobiomodulation with 940nm diode laser with the following parameters
Peak Power:0.2 Watts
Power density:0.7 Watt/cm2
Fluenc:7.14 J/cm 2 per sitting
Spot size:0.28cm2
Distance:
Extraoral: At skin surface (Contact mode)
Intraoral: 2mm from mucosal surface
Mode
Continuous
Sponsors
All India Institute of Medical Sciences
Eligibility
Inclusion criteria
Inclusion criteria: 1. All new diagnosed cases of Trigeminal neuralgia as per ICHD-3 criteria reporting to the department of OMR, CDER and willing to participate in the study will be included 2. Subjects diagnosed with Trigeminal neuralgia with a VAS score more than or equal to 5 3. Subjects willing to complete the treatment sessions
Exclusion criteria
Exclusion criteria: TN on polypharmacotherapy 2. TN secondary to multiple sclerosis, tumor, CNS lesions, herpes zoster or any other causes other than oral surgery. 3. TN in solely V1 distribution and acute TN 4. Past invasive treatment (MVD, alcohol block, cryosurgery, radiofrequency thermocoagulation, glycerol rhizolysis, gamma knife and stereotactic radiosurgery etc.) 5. Subjects with other orofacial pain like odontogenic/sinus/ occular otologic pain/ infection,TMD’s, myofascial pain , atypical orofacial pain, Burning mouth syndrome, traumatic neuropathy, or other neurological, psychiatric, neuromuscular and sensory disorders 6. Subjects on anti-inflammatories, analgesics, anaesthetics or any other medication for neurological disorders 7. Subjects with uncontrolled systemic diseases, with abnormal haemogram, liver function tests and renal function tests. 8. Subjects with current or past history of malignancy. 9. Alcoholics, drug addicts and patients with pacemaker. 10. Subjects with scars, tattoos, moles, traumatic, ulcerative, pathological skin lesion, open wounds, ulcers, or inflammation on facial skin in V2, V3 distribution sites to be exposed to Laser PBMT. 11. Subjects with bone marrow suppression, hypersensitivity to carbamazepine and tricyclic compounds 12. Pregnant and lactating females
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS score:Patients will be instructed to mark a single vertical line on a horizontally oriented, ungraduated 100-mm VAS labelled “no pain ? at the far left and “worst pain possible ? at the far right.Timepoint: Baseline, Day 3, Day 6, Day 9, Day 12, Day 15 before photobiomodulation therapy, Day2 and Day 30 post Photobiomodulation therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| BNI score ( Barrow Neurological Institute)Timepoint: Day3, Day 6, Day 9, Day 12, Day 15 before photobiomodulation therapy; Day 2 and Day 30 post photobiomodulation therapy;Oral health impact profile -14 score (OHIP-14)Timepoint: Baseline before photobiomodulation therapy, Day 2 and Day 30 post photobiomodulation therapy;Orofacial thermographyTimepoint: Baseline before photobiomodulation therapy, Day 2 and Day 30 post photobiomodulation therapy;Pain frequency ( Pain diary)Timepoint: Baseline, Day3, Day 6, Day 9, Day 12, Day 15 before photobiomodulation therapy; Day 2 and Day 30 post photobiomodulation therapy;VAS score:Patients will be instructed to mark a single vertical line on a horizontally oriented, ungraduated 100-mm VAS labelled “no pain ? at the far left and “worst pain possible ? at the far right.Timepoint: Day3, Day 6, Day9, Day 12, Day 15 before Photobiomodulation therapy | — |
Countries
India
Contacts
Public ContactDr Shugufta Khanam
All india Institute of Medical Sciences New Delhi
Outcome results
None listed